Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1987 1
1988 1
1991 1
2000 1
2001 3
2008 4
2012 1
2013 1
2015 1
2017 2
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Keech C, et al. Among authors: formica n. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2. N Engl J Med. 2020. PMID: 32877576 Free PMC article. Clinical Trial.
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, Robertson A, Dubovsky F, Glenn GM; 2019nCoV-101 Study Group. Formica N, et al. PLoS Med. 2021 Oct 1;18(10):e1003769. doi: 10.1371/journal.pmed.1003769. eCollection 2021 Oct. PLoS Med. 2021. PMID: 34597298 Free PMC article. Clinical Trial.
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J. Treanor JT, et al. Among authors: formica n. Vaccine. 2017 Apr 4;35(15):1856-1864. doi: 10.1016/j.vaccine.2017.02.066. Epub 2017 Mar 13. Vaccine. 2017. PMID: 28302411 Free article. Clinical Trial.
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.
Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM. Talbot HK, et al. Among authors: formica n. Vaccine. 2008 Jul 29;26(32):4057-61. doi: 10.1016/j.vaccine.2008.05.024. Epub 2008 Jun 2. Vaccine. 2008. PMID: 18602726 Free PMC article. Clinical Trial.
Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, Leong J. Airey J, et al. Among authors: formica n. Vaccine. 2017 May 9;35(20):2745-2752. doi: 10.1016/j.vaccine.2017.03.028. Epub 2017 Apr 5. Vaccine. 2017. PMID: 28390934 Free article. Clinical Trial.
Isotretinoin for refractory lupus erythematosus.
Shornick JK, Formica N, Parke AL. Shornick JK, et al. Among authors: formica n. J Am Acad Dermatol. 1991 Jan;24(1):49-52. doi: 10.1016/0190-9622(91)70008-p. J Am Acad Dermatol. 1991. PMID: 1999529
An indium tin oxide-free polymer solar cell on flexible glass.
Formica N, Mantilla-Perez P, Ghosh DS, Janner D, Chen TL, Huang M, Garner S, Martorell J, Pruneri V. Formica N, et al. ACS Appl Mater Interfaces. 2015 Mar 4;7(8):4541-8. doi: 10.1021/am5071909. Epub 2015 Feb 19. ACS Appl Mater Interfaces. 2015. PMID: 25654433 Free article.
Place of bupropion in smoking-cessation therapy.
Silagy C, Formica N. Silagy C, et al. Among authors: formica n. Lancet. 2001 May 19;357(9268):1550. doi: 10.1016/S0140-6736(00)04781-4. Lancet. 2001. PMID: 11377641 No abstract available.
19 results